1Bhana K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer[J]. Semin Oncol, 1998,25(Suppl 3): 19.
2Garces CA, Cance WG.Neoadjuvant chemotherapy of breast cancer[J]. Am Surg,2004,70(7) : 565.
3Dash N,Chafin SH ,Johnson RR,et al. Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer[J].AJR Am J Roentgenol, 1999,173(4) :911.
4Faneyte IF,Schrama JG,Peterse JL, et al.Breast cancer response to neoadjuvant chemotherapy :predictive markers and relation with outcome[J].Br J Cancer, 2003,88(3) : 406.
5Estevez LG,Sanchez-Rovira P.Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage Ⅱ and Ⅲ breast cancer patients:preliminary results of a phase Ⅱ and pharmacogenomic study[J]. Semin Oncol,2004,31:31.
6Musgrove EA,Davison EA,Ormandy CJ.Role of the Cdkinhibitor p27 (kip1)in mammary development and carcinogencsis : Insights from knockout mice[J].J Mammary Gland Bio Neoplasia,2004,9:55.
7Vincent-Salomon A, Rousseau A ,Jouve M,et al.Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthraeycline-based preoperative chemotherapy[J].Eur J Cancer,2004,40:1502.
8Burcombe R.l,Makris A ,Richman PI ,et al. Evaluation of ER PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycllne chemotherapy for operable breast cancer[J].Br J Cancer,2005, 92 : 147.
9Ellis P,Smith l,Ashley S,et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer[J].J Clin Oncol, 1998,16:107.
10Fisher ER,Wang J,Bryant J,et al.Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel(NSABP)protocol B-18[J].Cancer,2002,95:681.
